Session

IBD (Posters)

NEED FOR USTEKINUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE
NEED FOR USTEKINUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE

HEPATIC STEATOSIS BUT NOT FIBROSIS IS INDEPENDENTLY ASSOCIATED WITH A POOR OUTCOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
HEPATIC STEATOSIS BUT NOT FIBROSIS IS INDEPENDENTLY ASSOCIATED WITH A POOR OUTCOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

PROBIOTIC TREATMENT OF ULCERATIVE COLITIS WITH TRICHURIS SUIS OVA: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL
PROBIOTIC TREATMENT OF ULCERATIVE COLITIS WITH TRICHURIS SUIS OVA: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED CLINICAL TRIAL

A PH-SENSITIVE OPIOID PROVIDES SUSTAINED AND SAFE PAIN RELIEF BY TARGETING THE ACIDIFIED LAYERS OF THE INFLAMED COLON
A PH-SENSITIVE OPIOID PROVIDES SUSTAINED AND SAFE PAIN RELIEF BY TARGETING THE ACIDIFIED LAYERS OF THE INFLAMED COLON

EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA
EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA

LONG TERM SAFETY AND EFFICACY OF THIOPURINES WITHDRAWAL IN IBD PATIENTS
LONG TERM SAFETY AND EFFICACY OF THIOPURINES WITHDRAWAL IN IBD PATIENTS

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

MESENCHYMAL STEM CELLS INJECTION INTO COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: PRELIMINARY REAL-LIFE RESULTS
MESENCHYMAL STEM CELLS INJECTION INTO COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: PRELIMINARY REAL-LIFE RESULTS

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY
LONG-TERM TREATMENT PERSISTENCE OF ADALIMUMAB AND USTEKINUMAB IN BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE: A RETROSPECTIVE DATABASE STUDY

SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES
SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES

INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS

ACCUMULATION OF PRO-INFLAMMATORY CD4+ T CELLS AND ACTIVATED TCR VDELTA1+ T CELLS IN INFLAMED GUT TISSUE OF CROHN’S DISEASE PATIENTS
ACCUMULATION OF PRO-INFLAMMATORY CD4+ T CELLS AND ACTIVATED TCR VDELTA1+ T CELLS IN INFLAMED GUT TISSUE OF CROHN’S DISEASE PATIENTS

POSTOPERATIVE IMMUNOSUPPRESSIVE THERAPY DOES NOT INFLUENCE ENDOSCOPIC RECURRENCE RATES AFTER BOWEL RESECTIONS DUE TO CROHN’S DISEASE – A RETROSPECTIVE MULTICENTRE ANALYSIS
POSTOPERATIVE IMMUNOSUPPRESSIVE THERAPY DOES NOT INFLUENCE ENDOSCOPIC RECURRENCE RATES AFTER BOWEL RESECTIONS DUE TO CROHN’S DISEASE – A RETROSPECTIVE MULTICENTRE ANALYSIS

MUCIN MRNA ISOFORM SIGNATURES AS POTENTIAL NOVEL BIOMARKERS TO EVALUATE DISEASE STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
MUCIN MRNA ISOFORM SIGNATURES AS POTENTIAL NOVEL BIOMARKERS TO EVALUATE DISEASE STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS
VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

FACTORS ASSOCIATED WITH TREATMENT PERSISTENCE OF ANTI-TNF AGENTS AS FIRST LINE BIOLOGIC TREATMENT IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASES
FACTORS ASSOCIATED WITH TREATMENT PERSISTENCE OF ANTI-TNF AGENTS AS FIRST LINE BIOLOGIC TREATMENT IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASES

DIFFERENTIAL EXPRESSION OF MIR-424-5P AND MIR-378C IN STENOTIC AND PENETRATING LESSIONS OF CROHN’S DISEASE ASSOCIATES WITH ALTERED TRANSCRIPTION OF GENES INVOLVED IN VASCULAR REGULATION
DIFFERENTIAL EXPRESSION OF MIR-424-5P AND MIR-378C IN STENOTIC AND PENETRATING LESSIONS OF CROHN’S DISEASE ASSOCIATES WITH ALTERED TRANSCRIPTION OF GENES INVOLVED IN VASCULAR REGULATION

TELEMONITORING IBD WITH THE APP CARE4TODAY IBD: A REAL-LIFE CASE-CONTROL STUDY
TELEMONITORING IBD WITH THE APP CARE4TODAY IBD: A REAL-LIFE CASE-CONTROL STUDY

Item 101 - 120 / 612
1 2 3 4 5
6
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31